The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise (BALO)
The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise
In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.
The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.
Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Diepenbeek、ベルギー、3590
- Hasselt University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Obese group: BMI > 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant
- Lean controls: BMI > 18.5 kg/m² and < 25 kg/m², regular physical activity, insulin sensitive
Exclusion Criteria:
- Regular glucose lowering medication or beta blockade medication
- Presence of chronical diseases
- Orthopedic or neurological problems
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
persons with obesity
|
adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
|
lean persons
|
adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Subcutaneous adipose tissue microdialysis
時間枠:week 1
|
abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.
|
week 1
|
Atrial natriuretic peptide (ANP) Response
時間枠:week 1
|
measurement systemic ANP response (venous blood sampling)
|
week 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Central insulin sensitivity
時間枠:screening
|
Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)
|
screening
|
Echocardiography
時間枠:Day 1
|
heart function by means of standard echocardiography
|
Day 1
|
Maximal oxygen uptake (ml/O2/kg/min)
時間枠:Day 1
|
measured using indirect calorimetry and an incremental bicycle protocol
|
Day 1
|
Anthropometry
時間枠:screening
|
body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference
|
screening
|
Abdominal subcutaneous adipose tissue biopsy
時間枠:week 1
|
biochemical, proteomics and morphological analyses
|
week 1
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ellen Blaak, prof. dr.、Maastricht University
- スタディチェア:Kenneth Verboven, drs、Hasselt University
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CME2014 /450
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。